Literature DB >> 11709768

Combination vaccines: postlicensure safety evaluation.

R T Chen1, V Pool, H Takahashi, B G Weniger, B Patel.   

Abstract

The success of immunizations in nearly eliminating many vaccine-preventable diseases has resulted in an increase in the need to study risks from vaccines, combination or otherwise. The well-known limitations associated with prelicensure trials have led many to hope that postlicensure studies can address safety issues. This article reviews measures that have been or should be taken to meet this expectation: establishment of clinical immunization safety assessment centers, standardization of case definitions for vaccine adverse events, use of the Vaccine Identification Standards Initiative to improve the accuracy and efficiency with which vaccination records are transferred, integration of vaccine safety monitoring into immunization registries, establishment (and enlargement) of the Vaccine Safety Datalink project, use of innovative analytic tools for better signal detection, and implementation of various methods to overcome confounding by contraindication. Only by investing in vaccine safety infrastructure at a level commensurate with investments in vaccine development can we hope to retain the public's confidence in immunization.

Mesh:

Substances:

Year:  2001        PMID: 11709768     DOI: 10.1086/322569

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Safe motherhood in the United States: challenges for surveillance.

Authors:  Trude A Bennett; Melissa M Adams
Journal:  Matern Child Health J       Date:  2002-12

Review 2.  Placing the risk of seizures with pediatric vaccines in a clinical context.

Authors:  Robert L Davis; William Barlow
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 3.  Data mining in the US using the Vaccine Adverse Event Reporting System.

Authors:  John Iskander; Vitali Pool; Weigong Zhou; Roseanne English-Bullard
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

4.  Adverse Events Following Immunization in Brazil: Age of Child and Vaccine-Associated Risk Analysis Using Logistic Regression.

Authors:  Sílvia R C Lopes; João L R Perin; Taiane S Prass; Sandra Maria D Carvalho; Sérgio C Lessa; José G Dórea
Journal:  Int J Environ Res Public Health       Date:  2018-06-01       Impact factor: 3.390

5.  Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil.

Authors:  Mônica P L Cunha; José G Dórea; Rejane C Marques; Renata S Leão
Journal:  Biomed Res Int       Date:  2013-02-14       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.